๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-07-22

Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation (NCT07214220)

๐Ÿ”ต Active, Not Recruiting Observational / Diagnostic โš™๏ธ Medical Device Protocol Sponsor: Spryte Medical

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This is an investigational study for a new medical device called the nOCT (neuro optical coherence tomography) Imaging System, which is manufactured by Spryte Medical, LLC. The nOCT Imaging System takes pictures from inside a blood vessel in your brain. These pictures give your doctor information about the inside of your blood vessel including the disease and any implanted devices. The nOCT Imaging System consists of a probe and a console. The probe is a small, flexible wire-like device designed to navigate through catheters which have already been inserted in your body as part of your planned procedure. Catheters are small, flexible, tubes inserted in your blood vessels which allow your doctor to deliver treatments such as medications, coils, or stents directly to the affected area. The console is a unit that includes a computer, screen and laser light source. The probe is connected to the console. The console provides the probe with low-power light from the laser which is used to scan and create pictures of your blood vessel. The pictures are displayed on the screen of the console for review by your doctor and may be stored for future viewing. The objective of the study is to evaluate the safety and effectiveness of the nOCT Imaging System to provide quality images for diagnostic assessment during endovascular intracranial aneurysm treatment and follow-up.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (1 items).

Location: Baptist Health Research Institute โ€” Jacksonville, Florida

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Subjects with a minimum platelet count of \< 100,000/ฮผL. Subjects who have suffered an ischemic stroke or transient ischemic attack within the past 30 days. Subject has an acutely ruptured aneurysm with a Hunt \& Hess score โ‰ฅ 4 Subject has an infectious, blister-like, fusiform, dissecting, traumatic or mycotic aneurysm confirmed by angiography Subject has challenging anatomy that in the investigator's opinion is not suitable for safe delivery of an 0.021" catheter, including stenosis \> 70% or excessive tortuosity Subject presents with other medical or surgical co-morbidities limiting his/her life expectancy to less than one year Subject is, in the opinion of the investigator, unlikely to comply with the study protocol or follow-up requirements. Subject with any condition which in the opinion of the treating physician would place the subject at an elevated risk of embolic stroke Subject with known allergy or other contraindication to heparin, iodinated contrast, or dual-antiplatelet medication Subject has ipsilateral carotid or vertebral artery stenosis greater than 50% Subject underwent stenting, angioplasty, or endarterectomy procedures of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to treatment. Subject has serious concurrent medical conditions including bacteremia or sepsis, acute renal failure at the time of the procedure, and major coagulation system abnormalities that in the opinion of the investigator could significantly increase risk Subject has severe intracranial vasospasm not responsive to medical therapy Subject has chronic kidney disease stage โ‰ฅ 4 and is not undergoing dialysis The subject is pregnant or breastfeeding at the time of admission or plans to become pregnant during their participation in the trial Subject is currently participating in another clinical research trial involving an investigational device or drug Subject is under judicial protection or legal guardianship

๐Ÿ” Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

๐Ÿ“ All Participating Trial Locations (8 Sites)

  • Baptist Health Research Institute โ€” Jacksonville, Florida
  • Tampa General Hospital โ€” Tampa, Florida
  • Advocate Aurora Research Institute โ€” Park Ridge, Illinois
  • Tufts Medical Center, Inc. โ€” Boston, Massachusetts
  • Beth Israel Deaconess Medical Center โ€” Boston, Massachusetts
  • University at Buffalo Neurosurgery (UBNS) โ€” Buffalo, New York
  • ENERI - Clinica La Sagrada Familia Av del Libertador โ€” Buenos Aires,
  • St. Michael's Hospital โ€” Toronto,

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
๐Ÿ›๏ธ View Official NIH Record โ†—